# EFS

## Overview
The EFS gene encodes the embryonal Fyn-associated substrate protein, which is a member of the Crk-associated substrate (CAS) family. This family of proteins is integral to cellular signaling pathways, particularly through interactions with Src family kinases such as Src, Fyn, and Yes. The EFS protein functions as an adapter molecule, regulated by phosphorylation-dependent mechanisms, and plays a critical role in processes like cell adhesion, migration, and cytoskeletal organization (Sertkaya2014Decreased). Predominantly active in the cytoplasm and at cell membranes, EFS is involved in signal transduction pathways that mediate cellular responses to external stimuli, influencing growth and differentiation (Sertkaya2014Decreased). Its potential role as a tumor suppressor is underscored by its downregulation in certain cancers, such as prostate cancer, where it may inhibit malignant behavior (Sertkaya2014Decreased). Additionally, alterations in EFS methylation have been linked to poor prognosis in uveal melanoma, highlighting its clinical significance (Neumann2011EFS).

## Structure


## Function
The EFS (embryonal Fyn-associated substrate) gene encodes a protein that is part of the Crk-associated substrate (CAS) family, which includes proteins involved in cellular signaling pathways. EFS interacts with Src family kinases, such as Src, Fyn, and Yes, through an SH3 domain, suggesting its role as an adapter molecule regulated by phosphorylation-dependent mechanisms (Sertkaya2014Decreased). This interaction is crucial for processes like cell adhesion, migration, and cytoskeletal organization, which are essential for normal cellular physiology and development.

In healthy human cells, EFS is primarily active in the cytoplasm and at cell membranes, where it influences cellular processes such as growth and differentiation. The protein's activity in these locations suggests its involvement in signal transduction pathways that mediate responses to external stimuli, contributing to the regulation of cell behavior and function (Sertkaya2014Decreased).

While the specific function of EFS in healthy cells has not been extensively studied, its role in interacting with key signaling molecules indicates its importance in maintaining normal cellular functions and potentially acting as a tumor suppressor in certain contexts, as evidenced by its downregulation in prostate cancer (Sertkaya2014Decreased).

## Clinical Significance
The EFS (embryonal Fyn-associated substrate) gene is implicated in the progression of uveal melanoma (UM), a rare form of eye cancer. Alterations in the methylation status of the EFS gene have been associated with poor prognosis in UM. Specifically, biallelic methylation of the EFS gene is linked to reduced expression levels, which correlates with a higher risk of metastatic progression and decreased disease-free survival (Neumann2011EFS). The study by Neumann et al. found that tumors with complete or partial EFS methylation were more likely to lead to metastases, and all patients who died of metastases had EFS methylation in their primary tumors (Neumann2011EFS). This methylation is significantly correlated with chromosome 3 status and cell type, suggesting that EFS methylation could serve as a prognostic marker for UM (Neumann2011EFS).

The research suggests that EFS methylation is a site-directed de novo methylation mechanism, distinct from random epimutations, and may play a role in hematopoietic cell lineage differentiation (Neumann2011EFS). These findings highlight the clinical significance of EFS methylation in the context of UM, potentially guiding future diagnostic and therapeutic strategies.

## Interactions
EFS (embryonal Fyn-associated substrate) is a member of the Crk-associated substrate (CAS) family, which includes proteins such as BCAR1, NEDD9, and HEPL. These proteins are known for their roles in cellular physiology and malignant transformation. EFS interacts with Src family kinases, including Src, Fyn, and Yes, through an SH3 domain, similar to other CAS family members. This interaction suggests that EFS functions as an adapter molecule regulated by phosphorylation-dependent mechanisms (Sertkaya2014Decreased).

The interaction of EFS with these kinases is significant in the context of signal transduction pathways, where it may influence cellular processes like growth and differentiation. The SH3 domain-mediated interactions are part of a broader network of protein-protein interactions that EFS participates in, which includes its involvement in multiprotein complexes. These interactions are crucial for the regulation of EFS function and its potential role as a tumor suppressor gene in prostate cancer (Wu2007Systematic).

In prostate cancer, EFS expression is downregulated, and this downregulation is associated with DNA methylation. High EFS expression can suppress malignant behavior in prostate cancer cells, highlighting its potential role in inhibiting cancer progression (Sertkaya2014Decreased).


## References


[1. (Sertkaya2014Decreased) Selda Sertkaya, Syed Muhammad Hamid, Nihat Dilsiz, and Lokman Varisli. Decreased expression of efs is correlated with the advanced prostate cancer. Tumor Biology, 36(2):799–805, October 2014. URL: http://dx.doi.org/10.1007/s13277-014-2703-5, doi:10.1007/s13277-014-2703-5. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13277-014-2703-5)

[2. (Wu2007Systematic) Chenggang Wu, Mike Haiting Ma, Kevin R. Brown, Matt Geisler, Lei Li, Eve Tzeng, Christina Y. H. Jia, Igor Jurisica, and Shawn S.‐C. Li. Systematic identification of sh3 domain‐mediated human protein–protein interactions by peptide array target screening. PROTEOMICS, 7(11):1775–1785, May 2007. URL: http://dx.doi.org/10.1002/pmic.200601006, doi:10.1002/pmic.200601006. This article has 68 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/pmic.200601006)

[3. (Neumann2011EFS) Lisa C Neumann, Andreas Weinhäusel, Stefanie Thomas, Bernhard Horsthemke, Dietmar R Lohmann, and Michael Zeschnigk. Efs shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation. BMC Cancer, August 2011. URL: http://dx.doi.org/10.1186/1471-2407-11-380, doi:10.1186/1471-2407-11-380. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2407-11-380)